Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

The SynthNode Paradigm: Reimagining CAR T Cell Therapy for Improved Patient Outcomes

Award Number: R44CA310319
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/22/2025
PERIOD OF PERFORMANCE END DATE: 08/31/2026

Group Awards By:

View Award Description

The SynthNode Paradigm: Reimagining CAR T Cell Therapy for Improved Patient Outcomes - PROJECT SUMMARY CAR T cell therapy is a transformative approach in cancer treatment, particularly for treating lymphoma and myeloma, with emerging applications in solid tumors and non-cancer conditions such as lupus. Despite the remarkable success of CAR T cell therapy, widespread adoption has been hampered by the complex, labor- intensive, and costly production process that exists today. Delays in CAR T cell manufacturing can be detrimental, particularly for patients with rapidly progressing diseases. Approximately 20% of eligible patients are deprived of CAR T therapy due to production constraints that can delay therapy and compromise the potency and quality of the cell therapy product. Moreover, 40%–60% of patients who receive treatment eventually experience relapse in part due to poor CAR T cell persistence and expansion. Persistence Therapeutics Inc. is introducing a potentially revolutionary CAR T cell therapy approach called SynthNode. This implantable device, SynthNode, is the size of a dime and mimics the function of a synthetic lymph node, producing potent antigen- specific cells that durably persist for patient benefit. This solution is not only cost-effective and simpler to manufacture, but also produces CAR T cells with markedly enhanced potency and efficacy in eliminating tumors. By addressing the primary obstacles of cellular immunotherapy, this method promises to extend the accessibility and effectiveness of such treatments, even in resource-constrained environments. Furthermore, the use of biomaterial scaffolds represents a significant advancement in the field, offering a scalable and practical solution to the challenges faced by current CAR T cell manufacturing protocols. This fast-track Phase I/II proposal outlines a comprehensive plan of complete prototyping, non-GLP toxicology and large-animal efficacy testing, poising Persistence for an IDE-filing in 2027. The proposal is structured into two phases. Phase I focuses on optimizing SynthNode resulting in a design-locked formulation and determining the shelf life and in-use stability of the final formulation. Phase II focuses on scaling up SynthNode production, conducting a biocompatibility study per FDA standards, and performing large animal studies to ensure safety and efficacy at clinically relevant doses. With the completion of Phase II, the company will be ready to launch GLP toxicology studies for an Investigational Device Exemption (IDE) filing and first in human trials in 2028. This proposal addresses the urgent need for innovative solutions to enhance CAR T cell therapy and presents a clear, focused strategy to bring SynthNode from proof-of-concept animal studies to the clinic. Through meticulous planning, collaboration with manufacturing and regulatory experts, and a commitment to rigorous scientific investigation, Persistence Therapeutics Inc. is poised to make a significant impact on the future of cancer treatment.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	PERSISTENCE THERAPEUTICS, INC.	123 W FRANKLIN ST STE 550	CHAPEL HILL	NC	27516	ORANGE	USA	Cancer Treatment Research	000	1	12/9/2025	NEW	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $314,685 )
2025	2025	PERSISTENCE THERAPEUTICS, INC.	123 W FRANKLIN ST STE 550	CHAPEL HILL	NC	27516	ORANGE	USA	Cancer Treatment Research	000	1	9/22/2025	NEW	$314,685
														Subtotal = $314,685

Grand Total All Awards = $314,685

Top

All Categories

About

Search

Reports

Data Submission

Award Information

The SynthNode Paradigm: Reimagining CAR T Cell Therapy for Improved Patient Outcomes

Award Number: R44CA310319

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/22/2025

PERIOD OF PERFORMANCE END DATE: 08/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer